Mycosis Fungoides Treatment Market Size, Share & Industry Analysis, By Drug Type (Topical Steroids, Mechlorethamine , Interferons, Others), By Treatment (Photodynamic Therapy, Radiation Therapy, Chemotherapy, Others), By End User (Hospitals, Speciality Clinics, Others) and Regional Forecast, 2024-2032

Mycosis fungoides is a rare disease known as cutaneous T-cell lymphoma (CTCL). CTCL comprises of T-cell non-hodgkin lymphomas. This disease is considered to grow slow at an early stage and is mainly seen in a patient older than 50 years. The development of CTCL is most common in men when compared to women. Often the skin of a patient suffering from mycosis fungoides becomes infiltered leading to the formation of plaques and nodles that are composed of lymphocytes. This disease consists of four major stages with various different symptoms at each stage. In stage 1 general sign of mycosis fungoides with itching and pain in the affected area is observed. Stage 2 deals with the formation of plaque or infiltrating stage. Additionally, lymph nodes are formed. Furthermore, stage 3 is considered to be most important stage as the disease may lead to the formation of tumours which might spread throughout the body in stage 4.Various health complications can be observed once the disease is spread throughout the body which includes gastrointestinal problems, liver and speen enlargement, difficulty in swallowing, and in some cases, heart and brain may also be affected. Thus, different treatment is advised by physicians depending on the severity of the disease which is boosting the market growth during the forecast period. For instance, a combination of topical steroids and localized radiation is advised. For patients being diagnosed with stage 2 are recommended to HDAC inhibitors and extracorporeal photophoresis. Monoclonal antibodies are advised for patients suffering from the last stage of the disease.

Increase in prevalence of mycosis fungoides due to unhygenic lifestyle, increase in the geriatric patient population, a rise in large patient population suffering with the weak immune system, a rise in lymphoma cancer incidence, and others are some of the factors that are driving the growth of the market during the forecast period. According to the National Institute of Health (NIH), it is estimated that the prevalence rate of mycosis is 1 in per 100,000 to 350,000 individuals. Furthermore, a rise in demand for various treatment options based on the severity of the disease is also triggering market growth. This in turn, is boosting the manufacturers to launch new products for faster recovery. Along with this, technological advancement in the treatment of mycosis fungoides associated with chemotherapy is also propelling market growth. Moreover, the rise in demand for the monoclonal antibody as first-line therapy is also propagating the market growth in the near future.

Key Market Driver -

Increase in prevalence of mycosis fungoides

Key Market Restraint -

High cost of the treatment and high adverse effects

However, the high cost of the treatment, though the advancement in the treatment of mycosis fungoides is observed to excel in the medical field there are high adverse effects of this treatment which is limiting the growth of the market. For instance, treatment of advanced-stage mycosis fungoides are treated by multiagent chemotherapy which leads to adverse effects such as a decrease in white blood cell count, hair loss, vomiting, and others is also restraining the market growth.

Key Players Covered:

Some of the major companies that are present in the global mycosis Fungoides market are Astellas Pharma.Inc, Bayer AG, Novartis AG, Pfizer Inc, Merck & Co., Inc., GlaxoSmithKline plc, Abbott, Mylan N.V, and other players.

Increase in patients suffering with mycosis fungoides being diagnosed at their initial stage topical steroids in combination with localised radiation therapy is anticipated to dominate the market growth during the forecast period. In addition to this, increase in lymphocytes cancer is also boosting monoclonal antibodies treatment as the first line of therapy during the course of period.

Key Insights

• Prevalence of Mycosis Fungoides


• New product launches


• Key industry developments

Regional Analysis:

The global mycosis fungoides market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is dominating the market owing to increase in prevalence of mycosis fungoides, presence of major key players in the region such as Astellas Pharma.Inc, Pfizer.Inc, and others. According to, Cutaneous Lymphoma Foundation, it is estimated that around 3000 new cases of CTCL are reported every year in U.S. Europe is considered to second leading region due to increase in healthcare expenditure, increase in healthcare awareness, increase in new product launches, and others. Asia Pacific is also contributing towards the market growth owing to increase in geriatric patient population, a rise in collaboration of biopharmaceutical companies and research centre, and others. Latin America & Middle East & Africa is holding least market share due to low health awareness in the region, low economy emergence, and others.

To gain extensive insights into the market, Request for Customization

Segmentation

Key Industry Developments

• In August 2018, FDA approved new product named Poteligeo by Kyowa Kirin Co., for the treatment of mycosis fungoides. It is the humanised monoclonal antibody direct against CC chemokine receptor 4 (CCR4) which is frequently y used to treat blood cancer.


• In November 2017, FDA granted approval for Brentuximab Vendotin (Adcetris) for the treatment of primary Cutaneous anaplastic large cell lymphoma (pcALCL) and mycosis fungoides